(13S,14R)-13-methyl-15-propan-2-ylidene-12,14,16,17-tetrahydrocyclopenta[a]phenanthren-11-one
C21H22O — CID 135005249
Data last refreshed: (MolForge compound catalog, from PubChem)
About (13S,14R)-13-methyl-15-propan-2-ylidene-12,14,16,17-tetrahydrocyclopenta[a]phenanthren-11-one
(13S,14R)-13-methyl-15-propan-2-ylidene-12,14,16,17-tetrahydrocyclopenta[a]phenanthren-11-one (PubChem CID 135005249) has the molecular formula C21H22O and a molecular weight of 290.41 g/mol. Its IUPAC name is (13S,14R)-13-methyl-15-propan-2-ylidene-12,14,16,17-tetrahydrocyclopenta[a]phenanthren-11-one.
Molecular Properties
| Compound Name | (13S,14R)-13-methyl-15-propan-2-ylidene-12,14,16,17-tetrahydrocyclopenta[a]phenanthren-11-one |
|---|---|
| PubChem CID | 135005249 |
| Molecular Formula | C21H22O |
| Molecular Weight | 290.41 g/mol |
| Exact Mass | 290.17 |
| IUPAC Name | (13S,14R)-13-methyl-15-propan-2-ylidene-12,14,16,17-tetrahydrocyclopenta[a]phenanthren-11-one |
| SMILES | CC(C)=C1CC[C@@]2(C)CC(=O)c3c(ccc4ccccc34)[C@@H]12 |
| InChI | InChI=1S/C21H22O/c1-13(2)15-10-11-21(3)12-18(22)19-16-7-5-4-6-14(16)8-9-17(19)20(15)21/h4-9,20H,10-12H2,1-3H3/t20-,21+/m1/s1 |
| InChIKey | STQGLYJXGAOVEE-RTWAWAEBSA-N |
| XLogP | 5.65 |
| TPSA | 17.07 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 1 |
| Rotatable Bonds | |
| Heavy Atoms | 22 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 290.41 |
| LogP ≤ 5 | 5.65 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 1 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'isolated_alkene', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135005249 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.